Published in AIDS Res Hum Retroviruses on December 09, 2013
An Expanded Safety Study of Dapivirine Gel 4789 in Africa | NCT00917904
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch Sex Behav (2014) 0.93
Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv Transl Res (2015) 0.89
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release (2015) 0.83
Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. Contraception (2015) 0.83
Vaginal drug distribution modeling. Adv Drug Deliv Rev (2015) 0.83
Firmness Perception Influences Women's Preferences for Vaginal Suppositories. Pharmaceutics (2014) 0.82
Relationships between perceptual attributes and rheology in over-the-counter vaginal products: a potential tool for microbicide development. PLoS One (2014) 0.79
Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning. J Int AIDS Soc (2014) 0.78
The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development. PLoS One (2015) 0.77
Innovative sensory methods to access acceptability of mixed polymer semisoft ovules for microbicide applications. Drug Deliv Transl Res (2016) 0.75
Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. AIDS Res Hum Retroviruses (2016) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav (2006) 8.11
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
A vaginal fluid simulant. Contraception (1999) 3.36
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75
The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol (2009) 2.39
Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health (2004) 2.04
Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav (2007) 1.69
Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex (2010) 1.60
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis (2010) 1.55
Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS (2006) 1.51
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt) (2008) 1.40
Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow. J Pharm Sci (2008) 1.37
Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr (2010) 1.35
Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a Phase II Clinical Trial. J Acquir Immune Defic Syndr (2006) 1.30
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS (2011) 1.22
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther (2007) 1.13
Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol (2007) 1.13
Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sex Transm Infect (2010) 1.10
The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis (2006) 1.10
The effects of inhomogeneous boundary dilution on the coating flow of an anti-HIV microbicide vehicle. Phys Fluids (1994) (2011) 1.08
Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide. J Nonnewton Fluid Mech (2012) 1.07
A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect (2010) 1.06
Using modeling to help understand vaginal microbicide functionality and create better products. Drug Deliv Transl Res (2011) 1.06
Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J Acquir Immune Defic Syndr (2007) 1.04
Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci (2012) 1.03
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01
Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care (2007) 1.01
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci (2012) 1.01
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa. Contraception (2010) 0.96
Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med (2009) 0.92
Quantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: implications for microbicide development. Contraception (2011) 0.91
Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst Rev (2012) 0.87
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis (2012) 0.87
Rectal microbicide development. Curr Top Microbiol Immunol (2014) 0.87
UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother (2012) 0.82
Rheological properties of three different vitamin D ointments and their clinical perception by patients with mild to moderate psoriasis. J Eur Acad Dermatol Venereol (2005) 0.82
Measuring self-efficacy to use vaginal microbicides: the Microbicide Use Self-Efficacy instrument. Sex Health (2013) 0.81
Predicting subjective spreadability, viscosity, and stickiness. J Pharm Sci (1975) 0.80
The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781. J Acquir Immune Defic Syndr (2012) 0.80
The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials. PLoS One (2012) 0.77
A self-regulation program for maintenance of weight loss. N Engl J Med (2006) 7.49
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Stage-based expert systems to guide a population of primary care patients to quit smoking, eat healthier, prevent skin cancer, and receive regular mammograms. Prev Med (2005) 2.95
A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl (2005) 2.07
Challenges to improving the impact of worksite cancer prevention programs: comparing reach, enrollment, and attrition using active versus passive recruitment strategies. Ann Behav Med (2002) 1.75
Maintaining large weight losses: the role of behavioral and psychological factors. J Consult Clin Psychol (2008) 1.72
Social influences are associated with BMI and weight loss intentions in young adults. Obesity (Silver Spring) (2010) 1.69
Multiple risk expert systems interventions: impact of simultaneous stage-matched expert system interventions for smoking, high-fat diet, and sun exposure in a population of parents. Health Psychol (2004) 1.65
Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery. J Biomech Eng (2006) 1.60
STOP regain: are there negative effects of daily weighing? J Consult Clin Psychol (2007) 1.59
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
Combining behavioral weight loss treatment and a commercial program: a randomized clinical trial. Obesity (Silver Spring) (2013) 1.50
Internal disinhibition predicts weight regain following weight loss and weight loss maintenance. Obesity (Silver Spring) (2007) 1.46
Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun (2008) 1.42
Endocardial electrogram characteristics of epicardial ventricular arrhythmias. J Cardiovasc Electrophysiol (2013) 1.39
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
Gravity-induced coating flows of vaginal gel formulations: in vitro experimental analysis. J Pharm Sci (2004) 1.38
Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow. J Pharm Sci (2008) 1.37
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
A model of transluminal flow of an anti-HIV microbicide vehicle: Combined elastic squeezing and gravitational sliding. Phys Fluids (1994) (2008) 1.31
Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. Biophys J (2006) 1.31
Cultural translation of interventions: diabetes care in American Samoa. Am J Public Health (2010) 1.29
A prospective study of weight gain during the college freshman and sophomore years. Prev Med (2008) 1.29
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Changes in children's sleep duration on food intake, weight, and leptin. Pediatrics (2013) 1.26
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res (2010) 1.24
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
Identifying cluster subtypes for the prevention of adolescent smoking acquisition. Addict Behav (2006) 1.16
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing. J Pharm Sci (2007) 1.15
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr (2008) 1.15
Factorial invariance and internal consistency for the decisional balance inventory--short form. Addict Behav (2004) 1.14
Nurse-community health worker team improves diabetes care in American Samoa: results of a randomized controlled trial. Diabetes Care (2013) 1.13
Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med (2009) 1.13
Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol (2007) 1.13
Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res (2013) 1.12
Risk perception and smoking behavior in medically ill smokers: a prospective study. Addiction (2010) 1.11
Successful weight-loss maintenance in relation to method of weight loss. Obesity (Silver Spring) (2008) 1.11
Limiting variety in non-nutrient-dense, energy-dense foods during a lifestyle intervention: a randomized controlled trial. Am J Clin Nutr (2012) 1.11
Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception (2006) 1.10
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Compartmental transport model of microbicide delivery by an intravaginal ring. J Pharm Sci (2010) 1.09
Erosion of microbicide formulation coating layers: effects of contact and shearing with vaginal fluid or semen. J Pharm Sci (2005) 1.08
The effects of inhomogeneous boundary dilution on the coating flow of an anti-HIV microbicide vehicle. Phys Fluids (1994) (2011) 1.08
Living with Ma'i Suka: individual, familial, cultural, and environmental stress among patients with type 2 diabetes mellitus and their caregivers in American Samoa. Prev Chronic Dis (2008) 1.08
Smoking cessation among patients in an emergency chest pain observation unit: outcomes of the Chest Pain Smoking Study (CPSS). Nicotine Tob Res (2008) 1.07
Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide. J Nonnewton Fluid Mech (2012) 1.07
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04
Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J Acquir Immune Defic Syndr (2007) 1.04
Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci (2012) 1.03
Adding evidence-based behavioral weight loss strategies to a statewide wellness campaign: a randomized clinical trial. Am J Public Health (2014) 1.02
Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial. Arch Sex Behav (2009) 1.02
The utility of non-proportional quota sampling for recruiting at-risk women for microbicide research. AIDS Behav (2007) 1.02
A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci (2011) 1.01
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci (2012) 1.01
Translating Behavioral Interventions Onto mHealth Platforms: Developing Text Message Interventions for Smoking and Alcohol. JMIR Mhealth Uhealth (2015) 1.00
Multipurpose prevention technologies: products in development. Antiviral Res (2013) 1.00
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci (2007) 0.97
Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Biophys J (2009) 0.97
Three-year weight change in successful weight losers who lost weight on a low-carbohydrate diet. Obesity (Silver Spring) (2007) 0.96
Perceptions of e-prescribing efficiencies and inefficiencies in ambulatory care. Int J Med Inform (2010) 0.96
Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. PLoS One (2013) 0.95
Development and validation of the weight control strategies scale. Obesity (Silver Spring) (2013) 0.95
Reflections on CASA after 25 years. J Androl (2004) 0.95
Failure to meet weight loss expectations does not impact maintenance in successful weight losers. Obesity (Silver Spring) (2007) 0.95
The consequences of yield stress on deployment of a non-Newtonian anti-HIV microbicide gel. J Nonnewton Fluid Mech (2011) 0.95
A website to improve asthma care by suggesting patient questions for physicians: qualitative analysis of user experiences. J Med Internet Res (2007) 0.95
Biophysical analysis of prototype microbicidal gels. J Pharm Sci (2007) 0.93
User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch Sex Behav (2014) 0.93
Transient swelling, spreading, and drug delivery by a dissolved anti-HIV microbicide-bearing film. Phys Fluids (1994) (2013) 0.92
Evaluating nicotine replacement therapy and stage-based therapies in a population-based effectiveness trial. J Consult Clin Psychol (2006) 0.92
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Effect of temperature and pH on contraceptive gel viscosity. Contraception (2003) 0.91
Testing stage effects in an ethnically diverse sample. Addict Behav (2002) 0.91
Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Antiviral Res (2010) 0.90
Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. AIDS Res Hum Retroviruses (2012) 0.90
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures. J Acquir Immune Defic Syndr (2015) 0.89
Yoga as a complementary treatment for smoking cessation in women. J Womens Health (Larchmt) (2011) 0.89
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89